OT mobile menu

Search form


ASCO 2015

ASCO 2015

Sarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.

Advanced imaging techniques could allow clinicians the ability to determine as early as 9 days into sarcoma treatment whether the therapy will be effective in a given patient, according to a new University of Michigan study.

For the first time, researchers say they have been able to use a prostate fusion biopsy to determine which tumors are the most aggressive.

Not surprisingly, this was a very popular topic. I’m not sure why the ASCO planners didn’t anticipate this, because I had to wait a few minutes outside the door to even get in. At one point, it was standing room only!

Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.

In a heavily pretreated multiple myeloma (MM) population, daratumumab monotherapy at 16 mg/kg showed meaningful, durable, single-agent activity, with deep responses and a favorable safety profile, according to a new phase II study.

The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.


Subscribe to ASCO 2015 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.